Human invariant Vα24+ natural killer T cells activated by a-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells

Immunology

Volumn 99, Issue 2, 2000, Pages 229-234

  Nicol, A ^a,e   Nieda, M ^b   Koezuka, Y ^f   Porcelli, S ^c   Suzuki, K ^d   Tadokoro, K ^b   Durrant, S ^a   Juji, T ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Japanese Red Central Blood Center   (Japan)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALLOANTIGEN; CD1 ANTIGEN; GALACTOSYLCERAMIDE; LYMPHOKINE; PERFORIN; T LYMPHOCYTE RECEPTOR; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; PORE FORMING CYTOTOXIC PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MUTANT; CELL POPULATION; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DAUDI CELL; DENDRITE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTIC LEUKEMIA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; TUMOR CELL LINE; BLOOD DISEASE; CELL CULTURE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD1; CYTOTOXICITY, IMMUNOLOGIC; GALACTOSYLCERAMIDES; HEMATOLOGIC NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TUMOR CELLS, CULTURED;

EID: 0034133499     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.00952.x     Document Type: Article

References (25)

1. 1. Exley M., Porcelli S., Furman M., Garcia J. & Balk S. (1998) CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor a chains. J Exp Med 188, 867.
2. 2. Nieda M., Nicol A., Koezuka Y. et al. (1999) Activation of human Vα24NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24TCR-mediated manner. Hum Immunol 60, 10.
3. 3. Spada F.M., Koezuka Y. & Porcelli S.A. (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188, 1529.
4. 4. Brossay L., Chioda M., Burdin N. et al. (1998) CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188, 1521.
5. 5. Prussin C. & Foster B. (1997) TCR V alpha 24 and V beta 11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J Immunol 159, 5862.
6. 6. Davodeau F., Peyrat M., Necker A. et al. (1997) Close phenotypic and functional similarities between human and murine αβ T cells expressing invariant TCR α-chains. J Immunol 158, 5603.
7. 7. Exley M., Garcia J., Balk S.P. & Porcelli S. (1997) Requirements for CD1d recognition by human invariant Valpha24 + CD4-CD8-T cells. J Exp Med 186, 109.
8. 8. Poggi A., Costa P., Zocchi M.R. & Moretta L. (1997) Phenotypic and functional analysis of CD4 + NKRP1A + human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration. Eur J Immunol 27, 2345.
9. 9. Poggi A., Costa P., Morelli L. et al. (1996) Expression of human NKRP1A by CD34 + immature thymocytes: NKRP1A-mediated regulation of proliferation and cytolytic activity. Eur J Immunol 26, 1266.
10. 10. Reichlin A. & Yokoyama W.M. (1998) Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunol Cell Biol 76, 143.
11. 11. Asea A. & Stein-Streilein J. (1998) Signalling through NK1.1 triggers NK cells to die but induces NK T cells to produce interleukin-4. Immunology 93, 296.
12. 12. Porcelli S.A. (1995) The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol 59, 1.
13. 13. Porcelli S., Morita C.T. & Brenner M.B. (1992) CD1b restricts the response of human CD4-T lymphocytes to a microbial antigen. Nature 360, 593.
14. 14. Beckman E.M., Porcelli S.A., Morita C.T., Behar S.M., Furlong S.T. & Brenner M.B. (1994) Recognition of a lipid antigen by CD1-restricted + T cells. Nature 372, 691.
15. 15. Beckman E.M., Melian A., Behar S.M. et al. (1996) CDIc restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. J Immunol 157, 2795.
16. 16. Kawano T., Cui J., Koezuka Y. et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626.
17. 17. Oishi Y. & Iwamoto I. (1997) Role of TCR V alpha 24 J alpha Q + T cells in autoimmune diseases. Nippon Rinsho 55, 1425.
18. 18. Hammond K.J.L., Poulton L.D., Palmisano L.J., Silveira P.A., Godfrey D.I. & Baxter A.G. (1998) Alpha/beta T cell receptor (TCR) + CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD) /Lt mice by the influence of IL-4 and/or IL-10. J Exp Mal 187, 1047.
19. 19. Lehuen A., Lantz O., Beaudoin L. et al. (1998) Overexpression of natural killer T cells protects Vα14Jα281 transgeneic nonobese dibetic mice against diabetes. J Exp Med 188, 1831.
20. 20. Mieza M.A., Itoh T., Cui J.Q. et al. (1996) Selective reduction of V alpha 14 + NK T cells associated with disease development in autoimmune-prone mice. J Immunol 156, 4035.
21. 21. Nakagawa R., Motoki K., Ueno H. et al. (1998) Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 58, 1202.
22. 22. Morita M., Motoki K., Akimoto K. et al. (1995) Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38, 2176.
23. 23. Hsu F.J., Benike C., Fagnoni F. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nature Med 2, 52.
24. 24. Nieda M., Nicol A., Kikuchi A. et al. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8 + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91, 977.
25. 25. Jackman R.M., Stenger S., Lee A. et al. (1998) The tyrosine-containing cytoplasmic tail of CD1b is essential for its efficient presentation of bacterial lipid antigens. Immunity 8, 341.